BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

918 related articles for article (PubMed ID: 30585020)

  • 41. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
    Leenen CH; van Lier MG; van Doorn HC; van Leerdam ME; Kooi SG; de Waard J; Hoedemaeker RF; van den Ouweland AM; Hulspas SM; Dubbink HJ; Kuipers EJ; Wagner A; Dinjens WN; Steyerberg EW
    Gynecol Oncol; 2012 May; 125(2):414-20. PubMed ID: 22306203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
    Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
    Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
    Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA
    Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
    Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
    BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Expression of MMR in endometrial adenocarcinoma in women under 50 years old].
    Wu HX; Song JC; Shi YQ; Liu YX
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):733-6. PubMed ID: 23302332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer.
    Mrkonjic M; Turashvili G
    Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Universal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma.
    Gayhart MG; Johnson N; Paul A; Quillin JM; Hampton LJ; Idowu MO; Smith SC
    Am J Clin Pathol; 2020 Nov; 154(6):792-801. PubMed ID: 32789450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
    Backes FJ; Leon ME; Ivanov I; Suarez A; Frankel WL; Hampel H; Fowler JM; Copeland LJ; O'Malley DM; Cohn DE
    Gynecol Oncol; 2009 Sep; 114(3):486-90. PubMed ID: 19515405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart TL; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Cancer; 2021 Sep; 127(17):3082-3091. PubMed ID: 33983630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Hampel H; Pearlman R; de la Chapelle A; Pritchard CC; Zhao W; Jones D; Yilmaz A; Chen W; Frankel WL; Suarez AA; Cosgrove C; Backes F; Copeland L; Fowler J; O'Malley D; Salani R; McElroy JP; Stanich PP; Goodfellow P; Cohn DE
    Gynecol Oncol; 2021 Jan; 160(1):161-168. PubMed ID: 33393477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
    Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
    Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.
    Köbel M; Tessier-Cloutier B; Leo J; Hoang LN; Gilks CB; Soslow RA; Delair D; Stewart CJR; Lee CH
    Int J Gynecol Pathol; 2017 Nov; 36(6):555-561. PubMed ID: 28114191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.
    Bruegl AS; Ring KL; Daniels M; Fellman BM; Urbauer DL; Broaddus RR
    Cancer Prev Res (Phila); 2017 Feb; 10(2):108-115. PubMed ID: 27965287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel.
    O'Regan T; Chau K; Tatton M; Smith T; Parry S; Bissett I
    N Z Med J; 2013 Sep; 126(1382):70-7. PubMed ID: 24154771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer.
    Karpel HC; Smith M; Brodsky A; Pothuri B
    Gynecol Oncol; 2023 Aug; 175():20-24. PubMed ID: 37290248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial screening by immunohistochemistry is effective in universal screening for Lynch syndrome in endometrial cancer patients: a prospective observational study.
    Tsuruta T; Todo Y; Yamada R; Kuwahara K; Kurosu H; Minowa K; Minoura Y; Minobe S; Suzuki H; Kato H
    Jpn J Clin Oncol; 2022 Jul; 52(7):752-758. PubMed ID: 35438162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.